Pharvaris Says FDA Lifted Clinical Hold on Application for Deucrictibant
22 Janvier 2024 - 1:35PM
Dow Jones News
By Denny Jacob
Clinical-stage company Pharvaris said the U.S. Food and Drug
Administration lifted the clinical hold on the investigational new
drug application for deucrictibant for the prophylactic treatment
of hereditary angioedema attacks following a review of data from a
study.
"The lift of the clinical hold in the U.S. enables us to
progress the global development of deucrictibant for long-term
prophylaxis," including a resumed Phase 2 study in the U.S., said
Chief Executive Berndt Modig.
The FDA placed clinical studies of deucrictibant on hold in
August 2022.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 22, 2024 07:20 ET (12:20 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Pharvaris NV (NASDAQ:PHVS)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Pharvaris NV (NASDAQ:PHVS)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
